India, Feb. 11 -- IXP, a Lifesciences VC backed by JV Ventures, has announced the launch of it's first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from Pre-seed to Series A stages.

The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 200 crore with a greenshoe option of Rs 100 crore. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the lifesciences sector, the fund will invest across innovation in areas such as pharma, biotechnology, medical technology, speciality chemicals, agrotechnology and nutraceuticals.

Ketki Tulpule, Ph.D., CIO at IXP said, "IXP was born out of a need we saw in the Indian ...